In advanced gastric cancer, anti-PD-1 combination shows promise

  • Lancet Oncol

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In the first- or second-line setting of advanced gastric cancer, the combination of lenvatinib plus pembrolizumab achieved a higher response rate than either drug alone had shown in previous studies.

Why this matters

  • Many advanced gastric cancers are resistant or unresponsive to anti-programmed cell death protein 1 (anti-PD-1) drugs, underscoring the need for combination therapies.

Study design

  • Open-label, single group, phase 2 trial in Japan (n=29).
  • Funding: MSD.

Key results

  • 26 of 29 patients had an Eastern Cooperative Oncology Group performance status of 0.
  • 48% received treatment as first-line therapy, 52% as second-line therapy.
  • Median follow-up, 12.6 months.
  • Median PFS, 7.1 months.
  • 20 of 29 (69%) patients experienced an objective response.
    • The response rate was similar for first- and second-line treatments.
  • All patients achieved disease control.
  • Grade 3 treatment-related adverse events included hypertension (38%), proteinuria (17%), and platelet count decrease (7%).
  • There were no grade 4 treatment-related adverse events, serious treatment-related adverse events, or treatment-related deaths.

Limitations

  • Open-label, single institution.